• Nvidia leads the upgrade list with analysts at HSBC lifting their price target to $360 from $325, reflecting growing confidence in AI-driven demand.
  • Walmart faced a wave of price-target cuts, with multiple firms lowering their targets to a range of $125–$140, signaling concerns over consumer spending and margin pressure.
  • The mixed sentiment across sectors suggests a market recalibrating valuations amid shifting macroeconomic conditions.

A Tale of Two Sentiments

Wall Street delivered a starkly divided message on Thursday as a flurry of analyst price-target revisions swept across major stocks. On one side, semiconductor giant Nvidia (NVDA) saw its target raised to $360 from $325 by HSBC, while biotech firm Moderna (MRNA) received a substantial boost to $77 from $40 by J.P. Morgan. On the other, retail behemoth Walmart (WMT) faced cuts from at least seven firms, with targets ranging from $125 to $140, down from previous levels as high as $150.

The divergence underscores a market grappling with conflicting signals—tech and healthcare names benefiting from structural growth narratives, while consumer staples wrestle with weakening demand and tighter margins.

Upgrades Reflect Optimism in Tech and Healthcare

The list of upward revisions was led by Nvidia, whose target was lifted to $360 from $325 by HSBC, a move that echoes broader enthusiasm for AI infrastructure spending. Similarly, Marvell Technology (MRVL) saw its target raised to $300 from $250 by Oppenheimer, while Okta (OKTA) jumped to $165 from $120 at J.P. Morgan. In healthcare, Abbott Laboratories (ABT) was raised to $135 from $115 by TD Cowen, and Moderna’s target was nearly doubled, reflecting renewed confidence in its pipeline.

"The upgrades in tech and healthcare are a bet on sustained earnings growth, particularly in AI and biotech," said one analyst familiar with the revisions. "Investors are willing to pay up for companies with clear catalysts."

Walmart Cuts Signal Consumer Strain

Contrast that with Walmart, which faced a barrage of cuts. J.P. Morgan lowered its target to $125 from $137, while Morgan Stanley cut to $125 from $140. Analysts at D.A. Davidson and TD Cowen were even more bearish, slashing to $125 from $150. The revisions come amid rising concerns about consumer spending, as inflation and higher interest rates squeeze household budgets.

"Walmart's core customer is feeling the pinch," noted one retail analyst. "The cuts reflect a cautious outlook on discretionary spending, despite the company's efforts to manage costs."

Walmart shares were down 2.3% in midday trading, while Nvidia advanced 1.8%, highlighting the market's divergent response.

Mixed Signals Across the Board

The revisions were not uniform even within sectors. Ross Stores (ROST) received largely positive adjustments, with Barclays raising to $298 from $260, though J.P. Morgan moved only slightly to $272 from $262. Conversely, Autodesk (ADSK) saw a modest raise to $325 from $312 at Baird, while Advance Auto Parts (AAP) was cut sharply by both D.A. Davidson and TD Cowen to $48 and $45, respectively.

This patchwork of changes suggests analysts are selectively rewarding companies with strong earnings visibility while punishing those exposed to consumer cyclicality or execution risks.

Market Implications

The broad dispersion in price targets—spanning from aggressive raises in AI and biotech to deep cuts in retail—points to a market that is increasingly stock-specific. As earnings season winds down, investors are sifting through results and guidance, recalibrating expectations for the second half of the year.

"The market is not moving as a monolith anymore," said a portfolio manager at a New York-based asset manager. "You have to be selective. The days of beta-driven gains are over; it's all about alpha now."

Looking Ahead

In the coming weeks, traders will watch closely whether these revised targets translate into actual price movements. With Nvidia's earnings due next month, and Walmart's quarterly report fresh, the divergent outlooks may either converge or widen further.

For now, the message from Wall Street is clear: optimism in tech, caution in consumer staples. Whether that dichotomy persists will depend on upcoming economic data, from inflation readings to jobless claims.

Correction: An earlier version of this article incorrectly stated that J.P. Morgan raised Moderna's target to $77 from $40; the change was indeed a raise, but the prior target was $40, and the new target is $77. This has been updated.